Holen Sie sich die Stockscreener-App
8.08
9.82%
-0.88
Schlusskurs vom Vortag:
$8.96
Offen:
$8.94
24-Stunden-Volumen:
1.92M
Relative Volume:
0.85
Marktkapitalisierung:
$1.31B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-174.61M
KGV:
-4.1015
EPS:
-1.97
Netto-Cashflow:
$-165.54M
1W Leistung:
-5.16%
1M Leistung:
-13.30%
6M Leistung:
+11.37%
1J Leistung:
-30.58%
1-Tages-Spanne:
$7.90
$8.94
1-Wochen-Bereich:
$7.66
$9.318
52-Wochen-Spanne:
$5.9857
$11.84
89 Bio Inc Stock (ETNB) Company Profile
Firmenname
89 Bio Inc
Sektor
Branche
Telefon
(415) 432-9270
Adresse
142 SANSOME STREET, SAN FRANCISCO, CA
Vergleichen Sie ETNB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
8.08 | 1.31B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Fortgesetzt | BofA Securities | Buy |
| 2024-01-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-06-13 | Eingeleitet | Evercore ISI | Outperform |
| 2022-05-12 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-26 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-19 | Eingeleitet | Raymond James | Strong Buy |
| 2020-09-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-23 | Eingeleitet | BTIG Research | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-12-09 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-12-09 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
89 Bio Inc Aktie (ETNB) Neueste Nachrichten
Are 89bio Inc (NASDAQ: ETNB) Analysts Predicting A Spike? - Stocks Register
Victory Capital Management Inc. Acquires 1,437 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
PNC Financial Services Group Inc. Increases Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Given Sell (D-) Rating at Weiss Ratings - Defense World
89bio, Inc. (NASDAQ:ETNB) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $27.56 Average Target Price from Analysts - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Sold by Steward Partners Investment Advisory LLC - Defense World
89bio (NASDAQ:ETNB) Research Coverage Started at The Goldman Sachs Group - Defense World
Citigroup Initiates Coverage on 89bio (NASDAQ:ETNB) - Defense World
Goldman Sachs starts 89bio stock with neutral, $11 target By Investing.com - Investing.com Australia
Goldman Sachs Initiates Coverage of 89bio (ETNB) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage on 89bio With Neutral Rating, $11 Price Target -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Goldman Sachs starts 89bio stock with neutral, $11 target - Investing.com India
89bio initiated with a Neutral at Goldman Sachs - TipRanks
Commit To Buy 89bio At $7.50, Earn 25.1% Annualized Using Options - Nasdaq
Citigroup Initiates Coverage of 89bio (ETNB) with Buy Recommendation - Nasdaq
Citigroup Initiates 89bio Inc at Buy With $25 Price Target -March 13, 2025 at 07:13 am EDT - Marketscreener.com
89bio initiated with a Buy at Citi - TipRanks
Time nigh for I&I? Key data points ahead - BioWorld Online
89bio Inc (NASDAQ: ETNB) Is On The Fall - Stocks Register
89bio (NASDAQ:ETNB) Earns Sell (D-) Rating from Weiss Ratings - Defense World
Rhumbline Advisers Has $1.02 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - Citeline News & Insights
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
New York State Common Retirement Fund Has $128,000 Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Can 89bio's Liver Disease Pipeline Impress Investors at Upcoming Leerink Conference? - StockTitan
Cantor maintains Overweight on 89bio stock, price target at $29 - Investing.com
Cantor maintains Overweight on 89bio stock, price target at $29 By Investing.com - Investing.com UK
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy - Investing.com
89bio’s (ETNB) “Buy” Rating Reiterated at HC Wainwright - Defense World
89Bio Inc. Faces Financial Risks Amid Market Challenges for Approved Products - MSN
Decoding 89bio Inc (ETNB): A Strategic SWOT Insight - GuruFocus.com
89bio Inc. Advances Clinical Trials Amid Financial Losses - TipRanks
89bio (NASDAQ:ETNB) Stock Price Down 9.1%What's Next? - MarketBeat
89bio (NASDAQ:ETNB) Announces Earnings Results, Misses Estimates By $0.42 EPS - MarketBeat
Cantor Fitzgerald maintains 89bio stock with $29 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains 89bio stock with $29 target - Investing.com
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Globe and Mail
89bio, Inc. SEC 10-K Report - TradingView
89bio Secures $727.5M War Chest While Advancing Critical Phase 3 Trials — What's Next for ETNB? - StockTitan
89bio (ETNB) Projected to Post Earnings on Thursday - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $31.43 Consensus PT from Brokerages - Defense World
Weiss Ratings Reaffirms "Sell (D-)" Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Cell Sorting Market Size to Hit USD 601.89 Million by 2034 - BioSpace
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High? - MSN
89bio, Inc. (NASDAQ:ETNB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Should You Buy 89BIO (ETNB) After Golden Cross? - Nasdaq
Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - Defense World
Finanzdaten der 89 Bio Inc-Aktie (ETNB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):